Mobile Site ›

What the FDA Relabeling of Abacavir Means for You and Your Patient



Introduction

Slide 1

November 2008

Welcome to Mayo Medical Laboratories’ Hot Topics. These presentations provide short discussions of current topics and may be helpful to you in your practice.

Our presenters for this program are Dr. Dennis O’Kane and Dr. Joseph Yao.

Dr. O’Kane is co-director of the nucleotide polymorphism laboratory in the division of clinical biochemistry and immunology. Dr. Yao is from the Division of Clinical Microbiology at Mayo Clinic.

Dr. O’Kane and Dr. Yao will be discussing the recent FDA safety alert linking potentially fatal hypersensitivity reactions with abacavir, a nucleoside RT inhibitor of Human Immunodeficiency Virus to a specific HLA-B allele, HLA-B*5701, and what this means for patient care.

Introduction

 

Jump to section:


Key